Literature DB >> 29567826

Treatment and Survival of Patients with Colon Cancer Aged 80 Years and Older: A EURECCA International Comparison.

Nina C A Vermeer1, Yvette H M Claassen1, Marloes G M Derks1, Lene H Iversen2,3, Elizabeth van Eycken4, Marianne G Guren5, Pawel Mroczkowski6,7, Anna Martling8, Robert Johansson9, Tamara Vandendael4, Arne Wibe10, Bjorn Moller11, Hans Lippert6, Johanneke E A Portielje12, Gerrit Jan Liefers1, Koen C M J Peeters1, Cornelis J H van de Velde1, Esther Bastiaannet13,14.   

Abstract

BACKGROUND: Colon cancer in older patients represents a major public health issue. As older patients are hardly included in clinical trials, the optimal treatment of these patients remains unclear. The present international EURECCA comparison explores possible associations between treatment and survival outcomes in elderly colon cancer patients. SUBJECTS, MATERIALS, AND METHODS: National data from Belgium, Denmark, The Netherlands, Norway, and Sweden were obtained, as well as a multicenter surgery cohort from Germany. Patients aged 80 years and older, diagnosed with colon cancer between 2001 and 2010, were included. The study interval was divided into two periods: 2001-2006 and 2007-2010. The proportion of surgical treatment and chemotherapy within a country and its relation to relative survival were calculated for each time frame.
RESULTS: Overall, 50,761 patients were included. At least 94% of patients with stage II and III colon cancer underwent surgical removal of the tumor. For stage II-IV, the proportion of chemotherapy after surgery was highest in Belgium and lowest in The Netherlands and Norway. For stage III, it varied from 24.8% in Belgium and 3.9% in Norway. For stage III, a better adjusted relative survival between 2007 and 2010 was observed in Sweden (adjusted relative excess risk [RER] 0.64, 95% confidence interval [CI]: 0.54-0.76) and Norway (adjusted RER 0.81, 95% CI: 0.69-0.96) compared with Belgium.
CONCLUSION: There is substantial variation in the rate of treatment and survival between countries for patients with colon cancer aged 80 years or older. Despite higher prescription of adjuvant chemotherapy, poorer survival outcomes were observed in Belgium. No clear linear pattern between the proportion of chemotherapy and better adjusted relative survival was observed. IMPLICATIONS FOR PRACTICE: With the increasing growth of the older population, clinicians will be treating an increasing number of older patients diagnosed with colon cancer. No clear linear pattern between adjuvant chemotherapy and better adjusted relative survival was observed. Future studies should also include data on surgical quality. © AlphaMed Press 2018.

Entities:  

Keywords:  Adjuvant chemotherapy; Aged 80 and over; Colonic neoplasms; Europe; Surgery; Survival

Mesh:

Year:  2018        PMID: 29567826      PMCID: PMC6156182          DOI: 10.1634/theoncologist.2017-0551

Source DB:  PubMed          Journal:  Oncologist        ISSN: 1083-7159


  20 in total

Review 1.  EORTC Elderly Task Force experts' opinion for the treatment of colon cancer in older patients.

Authors:  A G Pallis; D Papamichael; R Audisio; M Peeters; G Folprecht; D Lacombe; E Van Cutsem
Journal:  Cancer Treat Rev       Date:  2009-11-26       Impact factor: 12.111

2.  Choosing the relative survival method for cancer survival estimation.

Authors:  Timo Hakulinen; Karri Seppä; Paul C Lambert
Journal:  Eur J Cancer       Date:  2011-05-04       Impact factor: 9.162

Review 3.  TNM staging system of colorectal carcinoma: a critical appraisal of challenging issues.

Authors:  Giacomo Puppa; Angelica Sonzogni; Romano Colombari; Giuseppe Pelosi
Journal:  Arch Pathol Lab Med       Date:  2010-06       Impact factor: 5.534

4.  Improved survival after an educational project on colon cancer management in the county of Stockholm--a population based cohort study.

Authors:  R Bernhoff; A Martling; A Sjövall; F Granath; W Hohenberger; T Holm
Journal:  Eur J Surg Oncol       Date:  2015-08-14       Impact factor: 4.424

5.  On-going improvement and persistent differences in the survival for patients with colon and rectum cancer across Europe 1999-2007 - Results from the EUROCARE-5 study.

Authors:  Bernd Holleczek; Silvia Rossi; Agius Domenic; Kaire Innos; Pamela Minicozzi; Silvia Francisci; Monika Hackl; Nora Eisemann; Hermann Brenner
Journal:  Eur J Cancer       Date:  2015-09-26       Impact factor: 9.162

6.  Global surveillance of cancer survival 1995-2009: analysis of individual data for 25,676,887 patients from 279 population-based registries in 67 countries (CONCORD-2).

Authors:  Claudia Allemani; Hannah K Weir; Helena Carreira; Rhea Harewood; Devon Spika; Xiao-Si Wang; Finian Bannon; Jane V Ahn; Christopher J Johnson; Audrey Bonaventure; Rafael Marcos-Gragera; Charles Stiller; Gulnar Azevedo e Silva; Wan-Qing Chen; Olufemi J Ogunbiyi; Bernard Rachet; Matthew J Soeberg; Hui You; Tomohiro Matsuda; Magdalena Bielska-Lasota; Hans Storm; Thomas C Tucker; Michel P Coleman
Journal:  Lancet       Date:  2014-11-26       Impact factor: 79.321

7.  Improved overall survival with oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment in stage II or III colon cancer in the MOSAIC trial.

Authors:  Thierry André; Corrado Boni; Matilde Navarro; Josep Tabernero; Tamas Hickish; Clare Topham; Andrea Bonetti; Philip Clingan; John Bridgewater; Fernando Rivera; Aimery de Gramont
Journal:  J Clin Oncol       Date:  2009-05-18       Impact factor: 44.544

8.  Treatment and complications in elderly stage III colon cancer patients in the Netherlands.

Authors:  K W J Hoeben; L N van Steenbergen; A J van de Wouw; H J Rutten; D J van Spronsen; M L G Janssen-Heijnen
Journal:  Ann Oncol       Date:  2012-11-07       Impact factor: 32.976

9.  Importance of the first postoperative year in the prognosis of elderly colorectal cancer patients.

Authors:  J W T Dekker; C B M van den Broek; E Bastiaannet; L G M van de Geest; R A E M Tollenaar; G J Liefers
Journal:  Ann Surg Oncol       Date:  2011-03-29       Impact factor: 5.344

10.  Trends in colorectal cancer mortality in Europe: retrospective analysis of the WHO mortality database.

Authors:  Driss Ait Ouakrim; Cécile Pizot; Magali Boniol; Matteo Malvezzi; Mathieu Boniol; Eva Negri; Maria Bota; Mark A Jenkins; Harry Bleiberg; Philippe Autier
Journal:  BMJ       Date:  2015-10-06
View more
  6 in total

1.  Efficacy and Safety of rCCK96-104PE38 Targeted Drug in the General Surgical Treatment of Colon Cancer.

Authors:  Wenbin Cao; Bo Zhang; Yang Liu
Journal:  Biomed Res Int       Date:  2022-06-08       Impact factor: 3.246

2.  The clinical features, management, and survival of elderly patients with colorectal cancer.

Authors:  Lei Shen; Ke Meng; Yifei Wang; Xiangli Yu; Ping Wang; Xiaomei Zhang
Journal:  J Gastrointest Oncol       Date:  2021-02

3.  M2 macrophage-derived exosomal microRNA-155-5p promotes the immune escape of colon cancer by downregulating ZC3H12B.

Authors:  Yu-Shui Ma; Ting-Miao Wu; Chang-Chun Ling; Fei Yu; Jie Zhang; Ping-Sheng Cao; Li-Peng Gu; Hui-Ming Wang; Hong Xu; Liu Li; Zhi-Jun Wu; Gao-Ren Wang; Wen Li; Qin-Lu Lin; Ji-Bin Liu; Da Fu
Journal:  Mol Ther Oncolytics       Date:  2021-02-06       Impact factor: 7.200

4.  Octogenarian patients with colon cancer - postoperative morbidity and mortality are the major challenges.

Authors:  Øystein Høydahl; Tom-Harald Edna; Athanasios Xanthoulis; Stian Lydersen; Birger Henning Endreseth
Journal:  BMC Cancer       Date:  2022-03-21       Impact factor: 4.430

5.  Octogenarians present with a less aggressive phenotype of colon adenocarcinoma.

Authors:  Naomi M Sell; Yasmeen Z Qwaider; Robert N Goldstone; Caitlin E Stafford; Christy E Cauley; Todd D Francone; Rocco Ricciardi; Liliana G Bordeianou; David L Berger; Hiroko Kunitake
Journal:  Surgery       Date:  2020-10-09       Impact factor: 3.982

6.  Surgical and functional outcomes and survival following Colon Cancer surgery in the aged: a study protocol for a prospective, observational multicentre study.

Authors:  Susanna Niemeläinen; Heini Huhtala; Anu Ehrlich; Jyrki Kössi; Esa Jämsen; Marja Hyöty
Journal:  BMC Cancer       Date:  2021-06-14       Impact factor: 4.430

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.